Eli Lilly & Co. (LLY) Tops Q4 EPS by 29c, Lifts Outlook

Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $2.09, $0.29 better than the analyst estimate of $1.80. Revenue for the quarter came in at $7.3 billion versus the consensus estimate of $7.35 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2023 EPS of $8.35-$8.55, versus the consensus of $8.28. Eli Lilly & Co. sees FY2023 revenue of $30.3-30.8 billion, versus the consensus of $30.55 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• FDA approves Lilly's once-weekly basal insulin for type 2 diabetes
• FDA clears Lilly's Olumiant for teens with severe alopecia areata